natgillin/translations-raw huggingface dataset:
Mean peak improvements in FEV1 within the first 6 hours following dosing relative to placebo was 224 ml (p &lt; 0.001) at Week 24.
Nakon 24 tjedna, srednje poboljšanje vršne vrijednosti FEV1 unutar prvih 6 sati nakon primjene lijeka u odnosu na placebo iznosilo je 224 ml (p &lt; 0,001*).
Mean plasma clearance following intravenous administration in cancer subjects was &gt; 200 L/h with moderate inter-subject variability (Coefficient of variation [CV] is approximately 50%).
Prosječna brzina uklanjanja iz plazme nakon intravenske primjene u ispitanika s karcinomom iznosila je &gt; 200 l/h uz umjerenu varijabilnost među ispitanicima (koeficijent varijacije [CV] približno je 50%).
Mean systemic emtricitabine exposure was higher in patients with severe renal impairment (CrCl &lt; 30 mL/min) (33.7 µg•h/mL) than in subjects with normal renal function (11.8 µg•h/mL).
Srednja vrijednost sistemske izloženosti emtricitabinu bila je viša u bolesnika s teškim oštećenjem funkcije bubrega (CrCl &lt; 30 ml/min) (33,7 µg•h/ml) nego u ispitanika s normalnom funkcijom bubrega (11,8 µg•h/ml).
Mean systemic emtricitabine exposure was higher in patients with severe renal impairment (CrCl &lt; 30 mL/min) (33.7 μg•h/mL) than in subjects with normal renal function (11.8 μg•h/mL).
Srednja vrijednost sistemske izloţenosti emtricitabinu bila je viša u bolesnika s teškim oštećenjem funkcije bubrega (CrCl &lt; 30 ml/min) (33,7 µg•h/ml) nego u ispitanika s normalnom funkcijom bubrega (11,8 µg•h/ml).
MedDRA conventions for frequency are very common (1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), or not known (cannot be estimated from the available data) including isolated reports.
Učestalost nuspojava prema MedDRA-i su: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka) uključujući izolirana izvješća.
Median 2.8 months (Range: 1.2 to &gt; 14.9 months)
Medijan 2,8 mjeseci (Raspon: 1,2 do &gt; 14,9 mjeseci)
Median age was 31 years (range: 18 to 61 years; 46.6% were &lt; 30 years at enrolment), 33.9% were male, and 89.0% were Caucasian.
Medijan dobi bio je 31 godina (raspon: 18 do 61 godine; 46,6% bilo je mlađe od 30 godina kod uključenja), 33,9% bilo je muškoga spola, a 89,0% bjelaca.
Median annualised bleeding rates in subjects &lt; 12 years of age evaluable for efficacy were 1.97 (interquartile range 0.00-3.13).
Medijan godišnjih stopa krvarenja u ispitanika u dobi &lt; 12 godina u kojih se mogla procijeniti djelotvornost iznosio je 1,97 (interkvartilni raspon 0,00-3,13).
Median cumulative illness rating score for geriatrics (CIRS-G) was 9 and 31% of patients had a CIRS-G &gt; 10.
Medijan rezultata na ljestvici za ocjenu kumulativne bolesti u starijih bolesnika (engl. cumulative illness rating score for geriatrics, CIRS-G) iznosio je 9, a 31% bolesnika imalo je CIRS-G rezultat &gt; 10.
Median Cumulative Illness Rating Score for Geriatrics (CIRS-G) was 9, and 31% of patients had a CIRS-G &gt; 10.
Medijan rezultata na ljestvici za ocjenu kumulativne bolesti u starijih bolesnika (engl. cumulative illness rating score for geriatrics, CIRS-G) iznosio je 9, a 31% bolesnika imalo je CIRS-G rezultat &gt; 10.
Median duration of treatment for all patients at 7 years of follow-up was 29.8 months (range &lt; 1-92.9 months).
Medijan trajanja liječenja za sve bolesnike u 7. godini praćenja iznosio je 29,8 mjeseci (raspon &lt; 1-92,9 mjeseci).
Median duration of treatment on dasatinib was 14 months with 31% of patients treated for &gt; 24 months to date.
Medijan trajanja liječenja dasatinibom iznosio je 14 mjeseci uz 31% bolesnika liječenih &gt; 24 mjeseca do tada.
Median duration of treatment on dasatinib was 24 months with 51% of patients treated for &gt; 24 months to date.
Medijan trajanja liječenja dasatinibom iznosio je 24 mjeseca, s time da je do tada 51% bolesnika bilo liječeno &gt; 24 mjeseca.
Median duration of treatment on dasatinib was 3 months with 2% treated for &gt; 24 months to date.
Medijan trajanja liječenja dasatinibom iznosio je 3 mjeseca, s time da je do tada 2% bolesnika bilo liječeno &gt; 24 mjeseca.
Median duration of treatment on dasatinib was 3 months with 7% of patients treated for &gt; 24 months to date.
Medijan trajanja liječenja dasatinibom iznosio je 3 mjeseca, s time da je do tada 7% bolesnika bilo liječeno &gt; 24 mjeseca.
Median duration of treatment on dasatinib was 3.5 months with 12% of patients treated for &gt; 24 months to date.
Medijan trajanja liječenja dasatinibom iznosio je 3,5 mjeseci, s time da je 12% bolesnika do tada bilo liječeno &gt; 24 mjeseca.
Median OS not reached for both arms. p &lt; 0.005 for OS.
Medijan OS nije dostignut za obje skupine. p &lt; 0,005 za OS.
Median OS not reached for both arms. p &lt; 0.005 for OS.
Medijan ukupnog preživljenja nije dostignut za obje skupine. p &lt; 0,005 za ukupno preživljenje.
Median PFS by investigator assessment was 30.7 months in the BR-CAP group and 16.1 months in the R- CHOP group (Hazard Ratio [HR]=0.51; p &lt; 0.001).
Medijan preživljenja bez progresije prema procjeni ispitivača bio je 30,7 mjeseci u BR-CAP skupini i 16,1 mjeseci u R-CHOP skupini (omjer hazarda [HR]=0,51; p &lt; 0,001).
Median PFS by investigator assessment was 30.7 months in the BzmbR-CAP group and 16.1 months in the R-CHOP group (Hazard Ratio [HR]=0.51; p &lt; 0.001).
Medijan preživljenja bez progresije prema procjeni ispitivača bio je 30,7 mjeseci u BzmbR-CAP skupini i 16,1 mjeseci u R-CHOP skupini (omjer hazarda [HR]=0,51; p &lt; 0,001).
Median PFS by investigator assessment was 30.7 months in the BzR-CAP group and 16.1 months in the R-CHOP group (Hazard Ratio [HR]=0.51; p &lt; 0.001).
Medijan preživljenja bez progresije prema procjeni ispitivača bio je 30,7 mjeseci u BzR-CAP skupini i 16,1 mjeseci u R-CHOP skupini (omjer hazarda [HR]=0,51; p &lt; 0,001).
Median PFS by investigator assessment was 30.7 months in the VcR-CAP group and 16.1 months in the R-CHOP group (Hazard Ratio [HR]=0.51; p &lt; 0.001).
Medijan preživljenja bez progresije prema procjeni ispitivača bio je 30,7 mjeseci u VcR-CAP skupini i 16,1 mjeseci u R-CHOP skupini (omjer hazarda [HR] = 0,51; p &lt; 0,001).
Median PFS increase 5.6 months, HR 0.421 (p &lt; 0.0001, 95% CI 0.343; 0.516)
Medijan produljenja preživljenja bez progresije bolesti: 5,6 mjeseci, HR = 0,421 (p &lt; 0,0001; 95% CI = 0,343; 0,516)
Median PFS times were 6.9 months (95% CI: 6.6, 8.3) for pemetrexed/cisplatin (HR=0.49; p-value &lt; 0.0001 for crizotinib compared with pemetrexed/cisplatin) and 7.0 months (95% CI: 5.9, 8.3) for pemetrexed/carboplatin (HR=0.45; p-value &lt; 0.0001 for crizotinib compared with pemetrexed/carboplatin).
Medijan PFS vremena bio je 6,9 mjeseci (95% CI: 6,6; 8,3) za pemetreksed/cisplatin (HR= 0,49; p- vrijednost &lt; 0,0001 za krizotinib u usporedbi s pemetreksedom/cisplatinom) i 7,0 mjeseca (95% CI: 5,9; 8,3) za pemetreksed/karboplatin (HR= 0,45; p-vrijednost &lt; 0,0001 za krizotinib u usporedbi s pemetreksedom/karboplatinom).
Median PFS was 15.7 months for patients on enzalutamide versus 5.8 months for patients on bicalutamide [HR = 0.44 (95% CI: 0.34, 0.57), p &lt; 0.0001].
Medijan PFS-a je bio 15,7 mjeseci za bolesnike na enzalutamidu naspram 5,8 mjeseci za bolesnike na bikalutamidu [HR = 0,44 (95% CI: 0,34; 0,57), p &lt; 0,0001].
Median platelet counts at baseline were 16,000/l for both treatment groups and in the eltrombopag group were maintained above 50,000/µl at all on-therapy visits starting at Day 15; in contrast, median platelet counts in the placebo group remained &lt; 30,000/µl throughout the study.
Medijan početnog broja trombocita je iznosio 16 000/l za obje ispitivane skupine, i u skupini liječenoj eltrombopagom njihov je broj održavan iznad 50 000/µl na svim kontrolnim pregledima tijekom liječenja počevši od 15. dana; nasuprot tome medijan broja trombocita u placebo skupini ostao je &lt; 30 000/µl tijekom cijelog ispitivanja.
Median time to angiomyolipoma progression was 11.4 months in the placebo arm and was not reached in the everolimus arm (HR 0.08; 95% CI: 0.02, 0.37; p &lt; 0.0001).
Medijan vremena do progresije angiomiolipoma bio je 11,4 mjeseci u skupini koja je primala placebo i nije bio postignut u everolimus skupini (HR 0,08; 95% CI: 0,02, 0,37; p &lt; 0,0001).
Median time to reach maximum plasma concentrations occurs between 1.5 to 3 hours after dosing, with low oral bioavailability ( &lt; 5%) due to significant first-pass metabolism.
Medijan vremena za postizanje maksimalnih koncentracija u plazmi pojavljuje se 1,5 do 3 sata nakon doziranja s niskom oralnom bioraspoloživošću ( &lt; 5%) zbog značajnog metabolizma prvog prolaza.
Medice Arzneimittel Pütter GmbH &amp; Co KG, Kuhloweg 37, D-58638 Iserlohn, Germany
Medice Arzneimittel Pütter GmbH &amp; Co KG, Kuhloweg 37, D-58638 Iserlohn, Njemačka
Medicinal products that are strong (causing a &gt; 5-fold increase in substrate clearance) or moderate (causing a 2-5 fold increase in substrate clearance) inducers of CYP3A are expected to decrease plasma concentrations of elvitegravir.
Lijekovi koji su jaki (uzrokuju &gt; 5-struko povećanje klirensa supstrata) ili umjereni induktori CYP3A (uzrokuju 2-5-struko povećanje klirensa supstrata) očekivano smanjuju koncentracije elvitegravira u plazmi.
Medium dose ICS ( &gt; 500 to 1000 micrograms BDP or equivalent/day)
Srednja doza inhalacijskog kortikosteroida ( &gt; 500 do 1000 mikrograma BDP-a ili ekvivalenta/dan)
Meloxidyl 0.5 mg/ml oral suspension for cats 15 &amp; 5 ml
Meloxidyl 0.5 mg/mL peroralna otopina za mačke 15 ml i 5 ml
Meloxidyl 20 mg/ml solution for injection for cattle, pigs, horses 50, 100, &amp; 250 ml
Meloxidyl 20 mg / ml, injekcijska otopina za goveda svinje i konje 50 ml, 100 ml i 250 ml
Men satisfying the International Society for Sexual Medicine (ISSM) criteria for premature ejaculation (PE) who had a baseline IELT ≤ 1 minutes in at least 2 of the first 3 sexual encounters during screening were eligible to enrol.
Dopušteno je uključivanje onim muškarcima koji su zadovoljavali kriterije Međunarodnog udruženja za seksualnu medicinu (ISSM) za preuranjenu ejakulaciju (PE) koja je postavila osnovnu vrijednost IELT &lt; 1 minute u najmanje 2 od prva 3 spolna odnosa.
Merck Sharp &amp; Dohme Animal Health S.L. Poligono Industrial El Montalvo I C/Zeppelin 6, Parcela 38
Merck Sharp &amp; Dohme Animal Helath S.L. Poligono Industrial E1 Moltalvo I C/Zeppelin 6, Parcela 38
MERCK SHARP &amp; DOHME ANIMAL HEALTH, S.L.
MERCK SHARP &amp; DOHME ANIMAL HEALTH S.L.
Merck Sharp &amp; Dohme B. V. Waarderweg 39
Merck Sharp &amp; Dohme BV Waarderweg 39,
Merck Sharp &amp; Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands
Merck Sharp &amp; Dohme B.V. Waarderweg 39 2031 BN Haarlem Nizozemska
Merck Sharp &amp; Dohme B.V., Waarderweg 39, P.O. Box 581, 2003 PC Haarlem, The Netherlands
Merck Sharp &amp; Dohme B.V., Waarderweg 39, P.O. Box 581, 2003 PC Haarlem, Nizozemska
Merck Sharp &amp; Dohme BV Waarderweg 39 2031 BN Haarlem The Netherlands
Merck Sharp &amp; Dohme BV Waarderweg 39 2013 BN Haarlem Nizozemska
Merck Sharp &amp; Dohme BV Waarderweg 39 2031 BN Haarlem The Netherlands
Merck Sharp &amp; Dohme BV Waarderweg 39 2031 BN Haarlem Nizozemska
Merck Sharp &amp; Dohme BV, Waarderweg 39, 2031 BN Haarlem, The Netherlands or
Merck Sharp &amp; Dohme BV, Waarderweg 39, 2031 BN Haarlem, Nizozemska ili
Merck Sharp &amp; Dohme Cyprus Limited
Merck Sharp &amp; Dohme OÜ Tel: +372.614.4200
Merck Sharp &amp; Dohme Cyprus Limited
Merck Sharp &amp; Dohme s.r.o.
Merck Sharp &amp; Dohme Cyprus Limited Τηλ: 800 00 673 (+357 22866700) cyprus_info@merck.com
Merck Sharp &amp; Dohme Cyprus Limited Τηλ.: 800 00 673 (+357 22866700) cyprus_info@merck.com
Merck Sharp &amp; Dohme Cyprus Limited., Tel: 8007 4433 (+356 99917558)
Merck Sharp &amp; Dohme OÜ, Tel: +372.
Merck Sharp &amp; Dohme d.o.o., Tel: +385 1 66 11 333
Merck Sharp &amp; Dohme d.o.o., Tel: +385 1 66 11
Merck Sharp &amp; Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp &amp; Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU Ujedinjeno Kraljevstvo
Merck Sharp &amp; Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp &amp; Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU Velika Britanija
Merck Sharp &amp; Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp &amp; Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU Ujedinjeno Kraljevstvo
Merck Sharp &amp; Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
Merck Sharp &amp; Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Ujedinjeno Kraljevstvo
Merck Sharp &amp; Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom.
Merck Sharp &amp; Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Velika Britanija.
Merck Sharp &amp; Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp &amp; Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU Ujedinjeno Kraljevstvo
Merck Sharp &amp; Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp &amp; Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU Velika Britanija
Merck Sharp &amp; Dohme OÜ Tel.: +372 6144 200 msdeesti@merck.com
Bristol-Myers Squibb GmbH &amp; CO.
Merck Sharp &amp; Dohme OÜ Tel.: +372 6144 200 msdeesti@merck.com
Merck Sharp &amp; Dohme OÜ Tel: +372 6144200 msdeesti@merck.com
Merck Sharp &amp; Dohme OÜ Tel: +372 6144 200 msdeesti@merck.com
Merck Sharp &amp; Dohme OÜ Tel: + 372 6144 200 msdeesti@merck.com
Merck Sharp &amp; Dohme OÜ, Tel: +372.614.4200
UAB Merck Sharp &amp; Dohme Tel.: +370.5.2780.247
Merck Sharp &amp; Dohme OÜ, Tel: +372.6144 200 Sanofi Pasteur MSD, Tlf: +47.67.50.50.20
Sanofi Pasteur MSD, Tlf: +47.67.50.50.20
Merck Sharp &amp; Dohme Romania S.R.L. Tel: + 40 21 529 2900 msdromania@merck.com
Merck Sharp &amp; Dohme Romania S.R.L. Tel: + 40 21 529 29 00 msdromania@merck.com
Merck Sharp &amp; Dohme Romania S.R.L. Tel: + 4021 529 29 00 msdromania@merck.com
Merck Sharp &amp; Dohme Romania S.R.L. Tel.: + 4021 529 29 00 msdromania@merck.com
Merck Sharp &amp; Dohme s.r.o, Tel.: +420.233.010.111
Merck Sharp &amp; Dohme s.r.o.
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o., Tel: +386.1.520.4201
Merck Sharp &amp; Dohme Romania S.R.L. Tel: + 4021 529 29 00
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o., Tel: +386.1.520.4201
SIA Merck Sharp &amp; Dohme Latvija Tel: +371.67364.224
Merck Sharp &amp; Dohme, Lda Tel: + 351 214 465700 clic@merck.com
Merck Sharp &amp; Dohme, Lda Tel: + 351 214 465 700 clic@merck.com
Merck Sharp &amp; Dohme, Lda.
Merck Sharp &amp; Dohme, Lda
Metabolism accounts for &lt; 10 % of the elimination of topotecan.
Metaboliziranjem se eliminira &lt; 10% topotekana.
Metabolism accounts for &lt; 10% of the elimination of topotecan.
Metaboliziranjem se eliminira &lt; 10% topotekana.
Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for &gt; 80% of an oral dose.
Glavni put eliminacije tenofoviralafenamida u ljudi je metabolizam kojim se razgradi &gt; 80% peroralne doze.
Metabolite concentrations represented &lt; 0.6% of parent compound, confirming that there are no major human metabolites of eribulin.
Koncentracije metabolita činile su &lt; 0,6% ishodišnog spoja, čime se potvrdilo da u ljudi ne nastaju neki važni metaboliti eribulina.
Methotrexate is contraindicated if bilirubin values are &gt; 5 mg/dl (85.5 µmol/L) (see section 4.3).
Metotreksat je kontraindiciran ako su vrijednosti bilirubina &gt; 5 mg/dl (85,5 µmol/l) (vidjeti dio 4.3).
Methylnaltrexone bromide-treated patients had a higher rate of laxation within 4 hours of the first dose (48 %) than placebo-treated patients (16 %); p &lt; 0.0001.
Bolesnici liječeni metilnaltreksonbromidom imali su veću stopu laksacije unutar 4 sata nakon davanja prve doze lijeka (48%) od bolesnika koji su primili placebo (16%); p &lt; 0,0001.
Methylnaltrexone bromide-treated patients had a higher rate of laxation within 4 hours of the first dose (48 %) than placebo-treated patients (16 %); p &lt; 0.0001. Methylnaltrexone bromide-treated patients also had significantly higher rates of laxation within
Bolesnici liječeni metilnaltreksonbromidom imali su veću stopu laksacije unutar 4 sata nakon davanja prve doze lijeka (48%) od bolesnika koji su primili placebo (16%); p &lt; 0,0001.
Methylnaltrexone bromide-treated patients had a significantly higher rate of laxation within 4 hours of the double-blind dose (62 % for 0.15 mg/kg and 58 % for 0.3 mg/kg) than placebo-treated patients (14 %); p &lt; 0.0001 for each dose versus placebo.
Bolesnici liječeni metilnaltreksonbromidom imali su značajno veću stopu laksacije unutar 4 sata nakon dvostruko slijepe doze (62% za 0,15 mg/kg i 58% za 0,3 mg/kg) od bolesnika koji su primili placebo (14%); p &lt; 0,0001 za svaku dozu u odnosu na placebo.
Micafungin demonstrated a smaller mean peak decrease in estimated glomerular filtration rate during treatment (p &lt; 0.001) and a lower incidence of infusion-related reactions (p=0.001) than liposomal amphotericin B.
Mikafungin je imao manju srednju vrijednost vršnog sniženja procijenjene brzine glomerularne filtracije tijekom liječenja (p &lt; 0,001) i nižu incidenciju reakcija povezanih s infuzijom (p = 0,001) od liposomalnog amfotericina B.
Micafungin treatment was associated with significant impairment of liver function (increase of ALT, AST or total bilirubin &gt; 3 times ULN) in both healthy volunteers and patients.
Liječenje mikafunginom bilo je povezano sa značajnim oštećenjem funkcije jetre (povišenje ALT-a, AST-a ili ukupnog bilirubina &gt; 3 puta iznad gornje granice normale) u zdravih dobrovoljaca i u bolesnika.
MicardisPlus should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.3).
MicardisPlus ne smije se primjenjivati kod bolesnika s teškim bubrežnim oštećenjem (klirens kreatinina &lt; 30 ml/min) (vidjeti dio 4.3).
Microspheres in the 1 to &lt; 10 µm diameter size range contribute to the contrast effect by generating strongly enhanced echoes.
Mikrosfere u rasponu promjera od 1 do &lt; 10 µm doprinose učinku kontrasta stvaranjem snažno pojačanih odjeka.
Mild ( &lt; LLN and &gt; 75 x 109/l) and transient decreases in platelet counts were observed at a higher incidence (12.7%) with Ilaris in the active-controlled clinical studies versus the comparator (7.7%) in gouty arthritis patients.
Blaga ( &lt; DGN i &gt; 75 x 109/l) i prolazna smanjenja broja trombocita zabilježena su uz veću incidenciju (12,7%) s Ilarisom u aktivno kontroliranim kliničkim ispitivanjima nego s komparatorom (7,7%) kod bolesnika s uričnim artritisom.
Mild and moderate renal impairment had no effect on trametinib exposure ( &lt; 6% for either group).
Blago i umjereno oštećenje bubrežne funkcije nije utjecalo na izloženost trametinibu ( &lt; 6% u svakoj skupini).
Mild GFR = 50-80 ml/min; Moderate GFR = 30-50 ml/min; Severe GFR = &lt; 30 ml/min
malo smanjenje brzine glomerularne filtracije (GFR) = 50-80 ml/min; umjereno smanjenje GFR = 30-50 ml/min; jako smanjenje GFR = &lt; 30 ml/min
Mild renal impairment (50 mL/min &lt; CrCLN &lt; 80 mL/min) does not appear to affect delamanid exposure.
Blago oštećenje bubrega (50 mL/min &lt; CrCLN &lt; 80 mL/min) ne čini se da utječe na izloženost delamanidu.
Mild renal impairment (creatinine clearance based on Cockcroft-Gault &lt; 80 ml/min and ≥ 50 ml/min) did not impact the pharmacokinetics of tocilizumab.
Blago oštećenje bubrega (klirens kreatinina na temelju Cockcroft-Gaultove jednadžbe &lt; 80 ml/min i ≥ 50 ml/min) nije utjecalo na farmakokinetiku tocilizumaba.
Mild to moderate renal impairment (creatinine clearance ≥30 to &lt; 90 ml/min) has no clinically important effect on the maximum elimination rate and systemic exposure (AUC and Cmax) of paclitaxel.
Blago do umjereno oštećenje bubrežne funkcije (klirens kreatinina od ≥ 30 do &lt; 90 ml/min) nema klinički važan učinak na maksimalnu brzinu eliminacije i sistemsku izloženost paklitakselu (AUC i Cmax).
Mild w/o ecchymosis, oozing and haematoma &lt; 5 cm
Blago bez ekhimoze, eksudata i hematoma &lt; 5 cm
Mildly decreased trabecular and cortical bone was seen in female rats administered ≥ 100 mg/kg/day (AUC exposure margin of 20.3-fold).
Blago smanjena trabekularna i kortikalna kost uočena je kod ženki štakora kod primjene &gt; 100 mg/kg/dan (granica AUC izloženosti od 20,3 puta).
Minimal accumulation of rasburicase ( &lt; 1.3 fold) was observed between days 1 and 5 of dosing.
Opažena je minimalna kumulacija razburikaze ( &lt; 1,3 puta) između 1. i 5. dana primjene.
Minimum inhibitory concentration (MIC) breakpoint established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for Staphylococci and Streptococci (except S. pneumoniae) are Susceptible ≤ 1 mg/l and Resistant &gt; 1 mg/l.
Granična minimalna inhibitorna koncentracija (MIK) koju je odredio Europski odbor za ispitivanje antimikrobne osjetljivosti (European Committee on Antimicrobial Susceptibility Testing, EUCAST) za stafilokoke i streptokoke (osim za S. pneumoniae) iznosi ≤1 mg/l za osjetljive i &gt; 1 mg/l za rezistentne.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL, 5 ml &amp; 10 ml
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NAJLJEPNICA NA BOČICI, 5 ml &amp; 10 ml
Minor bleeding occurred very commonly (1/10) and major bleeding occurred commonly (1/100 and &lt; 1/10).
Mala krvarenja pojavljivala su se vrlo često (1/10), a velika krvarenja pojavljivala su se često (1/100 i &lt; 1/10).
Minor bleeding occurred very commonly (1/10) and major bleeding occurred commonly (1/100 and &lt; 1/10).
Mala krvarenja pojavljivala su se vrlo često (1/10), a velika krvarenja često (1/100 i &lt; 1/10).
Mirabegron has not been studied in patients with end stage renal disease (GFR &lt; 15 mL/min/1.73 m2 or patients requiring haemodialysis).
Mirabegron nije ispitivan kod bolesnika u terminalnoj fazi bubrežne bolesti (GFR &lt; 15 ml/min/1,73 m2 ili bolesnicima na hemodijalizi).
Missed monthly maintenance dose ( &gt; 6 months)
Propuštanje mjesečne doze održavanja ( &gt; 6 mjeseci)
Missed monthly maintenance dose ( &gt; 6 weeks to 6 months)
Propuštanje mjesečne doze održavanja ( &gt; 6 tjedana do 6 mjeseci)
Missed second initiation dose ( &lt; 4 weeks from first injection)
Propuštanje druge početne doze ( &lt; 4 tjedna nakon prve injekcije)
Missed second initiation dose ( &gt; 7 weeks from first injection)
Propuštanje druge početne doze ( &gt; 7 tjedana nakon prve injekcije)
MIU = million international units; TIW = three times a week. a: p value based on Cochran-Mantel Haenszel Chi square test. b: p value based on chi-square test. c: subjects &lt; 75 kg received 100 µg/week PegIntron and subjects ≥ 75 kg received 150 µg/week PegIntron. d: ribavirin dosing was 800 mg for patients &lt; 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients &gt; 75 kg.
IU = milijun internacionalnih jedinica; a: p-vrijednost dobivena Cochran-Mantel Haenszelovim hi-kvadrat testom; b: p-vrijednost dobivena hi-kvadrat testom. c: ispitanici teški &lt; 75 kg primali su 100 μg lijeka PegIntron na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg lijeka PegIntron na tjedan. d: doza ribavirina iznosila je 800 mg za bolesnike &lt; 60 kg, 1000 mg za bolesnike 60-75 kg, te 1200 mg za bolesnike &gt; 75 kg.